Can-Fite unit fails Phase 2 glaucoma trial

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma.

No statistically significant differences were found between the CF101 treated group and the placebo group in the primary endpoint of lowering intra ocular pressure (IOP). High IOP is a characteristic of glaucoma. CF101 was found to have a favorable safety profile and was well tolerated.

“We are disappointed that CF101 failed to meet its primary endpoint, and based on these overall results we see no immediate path forward in glaucoma,” Pnina Fishman, CEO of Can Fite, said in a statement.